Maria Teresa Dotti, Jean-François Desaphy, Paola Imbrici, Diana Conte, Maria Rosaria Carratù, Michael G Hanna, Emma Matthews, Mauro Lo Monaco, Giovanni Meola, Rosanna Cardani, Concetta Altamura, Tiziana Mongini, Liliana Vercelli, Luisa Politano, Roberta Petillo, Paola D'Ambrosio, Giacomo P Comi, Gianna Ulzi, Dalila Sahbani, Sabrina Lucchiari
Journal: Human mutation 2019;39(9):1273-1283
PMID: 29935101
Myotonia congenita (MC) is a skeletal-muscle hyperexcitability disorder caused by loss-of-function mutations in the ClC-1 chloride channel. Mutations are scattered over the entire sequence of the channel protein, with more than 30 mutations located in the poorly characterized cytosolic C-terminal domain. In this study, we characterized, through patch clamp, seven ClC-1 mutations identified in patients affected by MC of various severities and located in the C-terminal region. The p.Val829Met, p.Thr832Ile, p.Val851Met, p.Gly859Val, and p.Leu861Pro mutations reside in the CBS2 domain, while p.Pro883Thr and p.Val947Glu are in the C-terminal peptide. We showed that the functional properties of mutant channels correlated with the clinical phenotypes of affected individuals. In addition, we defined clusters of ClC-1 mutations within CBS2 and C-terminal peptide subdomains that share the same functional defect: mutations between 829 and 835 residues and in residue 883 induced an alteration of voltage dependence, mutations between 851 and 859 residues, and in residue 947 induced a reduction of chloride currents, whereas mutations on 861 residue showed no obvious change in ClC-1 function. This study improves our understanding of the mechanisms underlying MC, sheds light on the role of the C-terminal region in ClC-1 function, and provides information to develop new antimyotonic drugs.
© 2018 Wiley Periodicals, Inc.
Full Text Sources:
Other Literature Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.